Trial
NCT04777708
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
Early Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
Merck Sharp & Dohme LLC; Highlight Therapeutics
Condition
Advanced Hepatocellular Carcinoma
Intervention
Nanoplexed Poly I:C BO-112
Why stopped
Withdrawn by sponsor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-24